- Home
- GTY vs IMCR Comparison
GTY vs IMCR Comparison
Compare GTY & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GTY | IMCR |
|---|---|---|
| Founded | 1955 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GTY | IMCR |
|---|---|---|
| Price | $29.83 | $31.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | $31.25 | ★ $64.30 |
| AVG Volume (30 Days) | 465.8K | ★ 517.7K |
| Earning Date | 02-11-2026 | 02-25-2026 |
| Dividend Yield | ★ 6.54% | N/A |
| EPS Growth | ★ 10.25 | N/A |
| EPS | ★ 1.28 | N/A |
| Revenue | $214,194,000.00 | ★ $379,590,000.00 |
| Revenue This Year | $6.51 | $32.42 |
| Revenue Next Year | $9.79 | $11.17 |
| P/E Ratio | $23.21 | ★ N/A |
| Revenue Growth | 8.17 | ★ 28.11 |
| 52 Week Low | $25.39 | $23.15 |
| 52 Week High | $32.17 | $40.72 |
Technical Indicators
Market Signals| Indicator | GTY | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 59.76 | 36.44 |
| Support Level | $28.72 | $31.68 |
| Resistance Level | $30.02 | $35.89 |
| Average True Range (ATR) | 0.50 | 1.54 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 68.75 | 10.13 |
Price Performance
Historical ComparisonAbout GTY Getty Realty Corporation
Getty Realty Corp is the real estate investment trust in the U.S. specializing in the acquisition, financing, and development of convenience, automotive, and other single tenant retail real estate. The company's portfolio includes convenience stores, car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, collision), automotive parts retailers, and certain other freestanding retail properties, including drive-thru quick service restaurants. It generates majority of the revenue in the form of rental income.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.